Literature DB >> 8938106

Interleukin-2 is indispensable for development of immunological self-tolerance.

G Klebb1, I B Autenrieth, H Haber, E Gillert, B Sadlack, K A Smith, I Horak.   

Abstract

Interleukin-2-deficient mice (IL-2(-/-)) manifest severe immune system abnormalities characterized by an uncontrolled activation and proliferation of lymphocytes. A systemic autoimmune syndrome results, and hemolytic anemia leads to early death especially in mice derived from a BALB/c genotype. Remarkably, IL-2 treatment prevents both the activation of the immune system and the development of autoimmune disease. Moreover, adoptive transfer of lymphocytes from IL-2-treated IL-2(-/-) animals confers protection to IL-2(-/-) mice, suggesting that IL-2 induces a postnatal differentiation/maturation of regulatory cells necessary for self- and non-self-discrimination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938106     DOI: 10.1006/clin.1996.0190

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  19 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination.

Authors:  Benjamin Anderschou Holbech Jensen; Maria Abildgaard Steffensen; Karen Nørgaard Nielsen; Jan Pravsgaard Christensen; Allan Randrup Thomsen; Peter Johannes Holst
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

3.  Early Subretinal Allograft Rejection Is Characterized by Innate Immune Activity.

Authors:  Kevin P Kennelly; Toby M Holmes; Deborah M Wallace; Cliona O'Farrelly; David J Keegan
Journal:  Cell Transplant       Date:  2017-01-20       Impact factor: 4.064

4.  Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.

Authors:  Ashutosh K Mangalam; David Luckey; Shailendra Giri; Michele Smart; Larry R Pease; Moses Rodriguez; Chella S David
Journal:  J Autoimmun       Date:  2012-03-28       Impact factor: 7.094

Review 5.  T cells as a therapeutic target in SLE.

Authors:  D Comte; M P Karampetsou; G C Tsokos
Journal:  Lupus       Date:  2015-04       Impact factor: 2.911

6.  The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Authors:  Sara E Martin del Campo; Kala M Levine; Bethany L Mundy-Bosse; Valerie P Grignol; Ene T Fairchild; Amanda R Campbell; Prashant Trikha; Thomas A Mace; Bonnie K Paul; Alena Cristina Jaime-Ramirez; Joseph Markowitz; Sri Vidya Kondadasula; Kristan D Guenterberg; Susan McClory; Volodymyr I Karpa; Xueliang Pan; Thomas E Olencki; J Paul Monk; Amir Mortazavi; Susheela Tridandapani; Gregory B Lesinski; John C Byrd; Michael A Caligiuri; Manisha H Shah; William E Carson
Journal:  J Immunol       Date:  2015-08-03       Impact factor: 5.422

7.  Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor.

Authors:  Deborah J Stauber; Erik W Debler; Patricia A Horton; Kendall A Smith; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

Review 8.  Interleukin 2: from immunostimulation to immunoregulation and back again.

Authors:  Martin F Bachmann; Annette Oxenius
Journal:  EMBO Rep       Date:  2007-12       Impact factor: 8.807

9.  Type I diabetes-associated tolerogenic properties of interleukin-2.

Authors:  Aziz Alami Chentoufi; Simon Gaudreau; Alex Nguyen; Mahmoud Sabha; Abdelaziz Amrani; Geyhad Elghazali
Journal:  Clin Dev Immunol       Date:  2011-05-10

10.  Conditional IL-2 Gene Deletion: Consequences for T Cell Proliferation.

Authors:  Zoran Popmihajlov; Dong Xu; Heather Morgan; Zoie Milligan; Kendall A Smith
Journal:  Front Immunol       Date:  2012-05-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.